|
|
| | TONABERSAT Basic information |
| Product Name: | TONABERSAT | | Synonyms: | TONABERSAT;N-[(3S,4S)-6-Acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-3- chloro-4-fluoro-benzamide;SB 22045;SB 220453;2H-Benzo(B)pyran-3-ol, 6-acetyl-4-(3-chloro-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-;Tonabersat [ban, inn];N-((3S,4S)-6-Acetyl-3-hydroxy-2,2-diMethylchroMan-4-yl)-3-chloro-4-fluorobenzaMide;Tonabersat (SB-220453) | | CAS: | 175013-84-0 | | MF: | C20H19ClFNO4 | | MW: | 391.82 | | EINECS: | | | Product Categories: | Aromatics Compounds;Aromatics;Heterocycles;Inhibitors | | Mol File: | 175013-84-0.mol |  |
| | TONABERSAT Chemical Properties |
| Boiling point | 554.5±50.0 °C(Predicted) | | density | 1.38 | | storage temp. | 2-8°C | | solubility | Soluble in DMSO | | pka | 11.86±0.60(Predicted) | | form | powder | | color | white to beige | | optical activity | [α]/D -100 to -110°, c = 1 in methanol |
| | TONABERSAT Usage And Synthesis |
| Uses | It is a cholinesterase inhibitor for treating and preventing migraine. An antimigraine agent. | | Biological Activity | migraine is a common, recurrent and primary headache disorder. optimisation of novel cis- and trans-4-(substituted-anfido)benzopyran-3-ol derivatives has led to the identification of tonabersat (sb-220453) with potential antimigraine activity. | | Biochem/physiol Actions | Tonabersat (SB-220453) exhibits anticonvulsant property. It is a member of the family of novel benzoylamino-benzopyran compounds. Tonabersat is used as a therapeutic for trigeminal nerve-induced neurovascular reflexes. In addition, it acts as a putative migraine prophylactic agent containing an unique stereospecific binding site in the brain. | | in vitro | topiramate targets multiple cortical and subcortical loci, altering voltage-gated ion channels and chemical transmission to decrease abnormal brain excitability. preclinical studies have identified four properties that may account for the drug’s efficacy in epilepsy and migraine prophylaxis: (i) blockage of voltage-dependent sodium channels; (ii) augmentation of the activity of the neurotransmitter g-aminobutyric acid (gaba) at some subtypes of the gaba-a receptor; (iii) antagonism of the ampa/kainate subtype of the glutamate receptor; and (iv) inhibition of the carbonic anhydrase enzymes, particularly isozymes ii and iv [1]. | | in vivo | tonabersat binds selectively to a unique site in the brain. moreover, tonabersat could markedly reduce cortical spreading depression (csd) and csd-associated events and inhibite gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion. together, these findings indicate that tonabersat should have clinical application in preventing migraine attacks [2]. | | references | [1] silberstein sd. tonabersat, a novel gap-junction modulator for the prevention of migraine. cephalalgia. 2009;29 suppl 2:28-35.
[2] durham pl, garrett fg. neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. cephalalgia. 2009;29 suppl 2:1-6.
[3] hauge aw, asghar ms, schytz hw, christensen k, olesen j. effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. lancet neurol. 2009;8(8):718-23. |
| | TONABERSAT Preparation Products And Raw materials |
|